Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUWJI4)

• Drug Name: E-6700 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9843006
  TTD Drug ID: DMUWJI4

Molecule-Related Drug Atlas

Drug(s) Targeting Arachidonate 5-lipoxygenase (5-LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[2]
Diethylcarbamazine	DM1TJ8F	Elephantiasis		Approved	[3]
Silymarin	DMXBYQR	N. A.	N. A.	Phase 4	[4]
3,4-Dihydroxycinnamic Acid	DMVZL26	Thrombocytopenia	3B64	Phase 4	[5]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
ABT-761	DM3FIC2	Asthma	CA23	Phase 3	[7]
Tenidap	DMHQRYE	Rheumatoid arthritis	FA20	Phase 3	[8]
FPL-62064	DMGF8MZ	Inflammation	1A00-CA43.1	Phase 3	[9]
Flobufen	DMPSG4D	Rheumatoid arthritis	FA20	Phase 3	[10]
Darbufelone	DMYVKM5	Asthma	CA23	Phase 2/3	[11]

Drug(s) Targeting Thromboxane-A synthase (TBXAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PYRIDINE	DMF8CJ9	N. A.	N. A.	Phase 4	[12]
NM-702	DMDJLY9	Angina pectoris	BA40	Phase 3	[13]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[14]
EV-077	DM1FCDH	Type-2 diabetes	5A11	Phase 2	[15]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[16]
NV-52	DM0UOA9	Inflammatory bowel disease	DD72	Phase 1	[17]
Satigrel	DM4LSJ2	Thrombosis	DB61-GB90	Discontinued in Preregistration	[18]
MILACAINIDE TARTRATE	DMJLNUD	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[19]
Imitrodast	DMQ2ULV	Asthma	CA23	Discontinued in Phase 2	[20]
Rolafagrel	DM8Q7XV	Nephritis	GB40	Discontinued in Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Modulator	[1]
Thromboxane-A synthase (TBXAS1)	TTKNWZ4	THAS_HUMAN	Modulator	[1]

References

• [1] Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
• [2] 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
• [3] Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
• [4] Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
• [5] Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
• [6] Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
• [7] Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
• [8] The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
• [9] FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
• [10] Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
• [11] Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
• [12] Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
• [13] The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
• [14] Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
• [15] Company report (Pharmaceuticalintelligence)
• [16] G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
• [17] Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
• [18] Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
• [19] Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
• [20] RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.
• [21] Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:707-10.